Knee joint wear is a common issue that causes pain and makes everyday movement difficult. Many people and clinicians look for treatments that are effective yet avoid the complications of surgery. This article explains what ChondroFiller is made of, how it works, and what the published evidence says about its safety — keeping expectations realistic from the outset.

What Is ChondroFiller Made Of?

ChondroFiller is a Class III CE-marked medical device composed of two components: a solution of type I collagen (purified from the tail tendons of specific pathogen-free rats bred under strictly controlled conditions) and a mild, pH-balanced neutralising solution. These are supplied in a sterile, single-use, double-chamber syringe and mixed at the time of treatment. When the two components combine, the pH shift triggers fibrillogenesis — the collagen molecules assemble into fibres — and the mixture sets into a self-adherent hydrogel within approximately three to five minutes. The final implant contains no hyaluronic acid and no living cells; it is entirely acellular.

The manufacturing process is strictly regulated. ChondroFiller is classified as a Class III medical device under EU Regulation 2017/745, which demands the most rigorous clinical evaluation and post-market surveillance of any device category. CE marking and the published clinical evidence base belong to ChondroFiller as a device.

How Does ChondroFiller Work?

ChondroFiller is delivered as a non-surgical, ultrasound-guided outpatient injection through a fine needle directly into the knee joint. Once inside the defect, the gel settles into the three-dimensional geometry of the cartilage lesion. Because it is self-adherent — forming stable bonds with endogenous fibrin in the surrounding tissue — it remains fixed without sutures or added fibrin glue.

The therapeutic action is based on acellular matrix-induced chondrogenesis. The implanted type I collagen scaffold acts as a chemotactic stimulus, attracting the patient's own progenitor cells from the synovium and subchondral bone marrow into the defect. Once recruited, these cells migrate into the scaffold, differentiate into chondrocyte-like cells, and begin synthesising new cartilage matrix, including type II collagen. Over a residence time of roughly one to two years, the scaffold is gradually resorbed and replaced by patient-derived tissue. The gel may settle over worn surfaces, adding a protective, cushioning layer — but it is best understood as a biologically supportive scaffold, not a guaranteed repair, cure, or reversal of arthritis.

Is ChondroFiller Safe? What Do Studies Show?

Patient safety is always a priority. The published safety profile of ChondroFiller is reassuring. Across more than 19,000 units sold since 2013, no serious device-related incidents have been reported. The overall complaint rate has been very low, with non-gelation — the most common device-related issue — occurring rarely. Clinical studies consistently report a near-zero rate of complications, which compares favourably with more invasive surgical alternatives.

Published outcomes data support both safety and efficacy. In knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over 12 to 36 months. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores in knee studies have been reported at around 80 and above, indicating high-quality tissue fill. A 2023 study in trapeziometacarpal (thumb-base) osteoarthritis reported improvements in pain and grip strength (Corain et al., 2023, Cartilage). ChondroFiller is generally well tolerated when used appropriately and with careful patient selection.

The biomechanical study by Weizel et al. (2020, Acta Biomaterialia) examined the mechanical properties of collagen hydrogels in relation to articular cartilage. It is a material-science reference and does not report clinical patient outcomes; its findings should not be cited as clinical evidence of symptom improvement.

What Can Patients Expect?

ChondroFiller is delivered as an outpatient injection. There is no theatre, no incision, and no general anaesthetic. Recovery is straightforward: most people are up and about the same day and return to normal activities promptly, without the rehabilitation demands of open surgery. Responses vary between patients, and benefits cannot be guaranteed — the extent of improvement depends on lesion size, location, grade, and individual biology.

ChondroFiller is intended for ICRS Grade I–IV cartilage defects up to approximately 6 cm² across a range of joints. Careful clinical assessment before treatment is essential to establish whether a patient is a suitable candidate; contraindications and lesion characteristics influence that decision.

How ChondroFiller Fits Within a Broader Treatment Pathway

ChondroFiller as an injection is suited to accessible lesions where a non-surgical approach is appropriate. For larger, load-bearing defects — or where the clinical picture calls for surgical preparation of the defect, the addition of biological adjuncts such as platelet-rich fibrin or the patient's own mesenchymal stem cells, and a structured peri-operative programme — a keyhole surgical approach may be more appropriate. At the London Cartilage Clinic, cartilage specialists assess each patient individually to determine the right pathway, whether that is the ChondroFiller injection or a more involved surgical procedure. Distinguishing between these options is part of a thorough pre-treatment consultation.

In Summary

ChondroFiller's biocompatible, acellular, CE-marked collagen scaffold and its reassuring published safety record make it a rational non-surgical option for many people with knee joint wear. The injection may add a supportive, protective layer over damaged cartilage surfaces, but it is not a cure and outcomes vary. For advice tailored to your specific joint, a consultation with a cartilage specialist is the appropriate next step.

References

• Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
• Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.